HPCAL1

Summary

HPCAL1 (hippocalcin like 1, HGNC:5145) is a protein-coding gene on chromosome 2p25.1, encoding Hippocalcin-like protein 1 (P37235). May be involved in the calcium-dependent regulation of rhodopsin phosphorylation.

The protein encoded by this gene is a member of neuron-specific calcium-binding proteins family found in the retina and brain. It is highly similar to human hippocalcin protein and nearly identical to the rat and mouse hippocalcin like-1 proteins. It may be involved in the calcium-dependent regulation of rhodopsin phosphorylation and may be of relevance for neuronal signalling in the central nervous system. Several alternatively spliced transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 3241 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 25 total
• Druggable target: yes
• MANE Select transcript: NM_002149

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5145
Approved symbol	HPCAL1
Name	hippocalcin like 1
Location	2p25.1
Locus type	gene with protein product
Status	Approved
Aliases	BDR1, HLP2, VILIP-3
Ensembl gene	ENSG00000115756
Ensembl biotype	protein_coding
OMIM	600207
Entrez	3241

Gene structure

Transcript identifiers

Ensembl transcripts: 99 — 98 protein_coding, 1 nonsense_mediated_decay

ENST00000307845, ENST00000381765, ENST00000419810, ENST00000422133, ENST00000423674, ENST00000613496, ENST00000620771, ENST00000622018, ENST00000904522, ENST00000904523, ENST00000904524, ENST00000904525, ENST00000904526, ENST00000904527, ENST00000904528, ENST00000904529, ENST00000904530, ENST00000904531, ENST00000904532, ENST00000904533, ENST00000904534, ENST00000904535, ENST00000904536, ENST00000904537, ENST00000904538, ENST00000904539, ENST00000904540, ENST00000904541, ENST00000904542, ENST00000904543, ENST00000904544, ENST00000904545, ENST00000904546, ENST00000904547, ENST00000904548, ENST00000904549, ENST00000904550, ENST00000904551, ENST00000904552, ENST00000904553, ENST00000904554, ENST00000904555, ENST00000904556, ENST00000904557, ENST00000904558, ENST00000904559, ENST00000904560, ENST00000904561, ENST00000904562, ENST00000904563, ENST00000904564, ENST00000904565, ENST00000904566, ENST00000904567, ENST00000904568, ENST00000904569, ENST00000904570, ENST00000904571, ENST00000904572, ENST00000904573, ENST00000904574, ENST00000904575, ENST00000904576, ENST00000904577, ENST00000926826, ENST00000926827, ENST00000926828, ENST00000926829, ENST00000959392, ENST00000959393, ENST00000959394, ENST00000959395, ENST00000959396, ENST00000959397, ENST00000959398, ENST00000959399, ENST00000959400, ENST00000959401, ENST00000959402, ENST00000959403, ENST00000959404, ENST00000959405, ENST00000959406, ENST00000959407, ENST00000959408, ENST00000959409, ENST00000959410, ENST00000959411, ENST00000959412, ENST00000959413, ENST00000959414, ENST00000959415, ENST00000959416, ENST00000959417, ENST00000959418, ENST00000959419, ENST00000959420, ENST00000959421, ENST00000959422

RefSeq mRNA: 5 — MANE Select: NM_002149 NM_001258357, NM_001258358, NM_001258359, NM_002149, NM_134421

CCDS: CCDS1671

Canonical transcript exons

ENST00000307845 — 5 exons

Exon	Start	End
ENSE00000804734	10419734	10420135
ENSE00001137728	10396835	10396920
ENSE00001640994	10422983	10423088
ENSE00001813124	10302904	10303177
ENSE00001932779	10426724	10427604

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 99.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.2851 / max 283.5447, expressed in 1808 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
18821	27.7799	1805
18822	1.9677	1072
18848	0.2220	84
18849	0.1311	41
18832	0.1144	47
18831	0.0560	28
202076	0.0141	5

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar vermis	UBERON:0004720	99.61	gold quality
cerebellum	UBERON:0002037	99.41	gold quality
cerebellar cortex	UBERON:0002129	99.41	gold quality
cerebellar hemisphere	UBERON:0002245	99.41	gold quality
paraflocculus	UBERON:0005351	99.41	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.39	gold quality
frontal pole	UBERON:0002795	98.61	gold quality
Brodmann (1909) area 10	UBERON:0013541	98.51	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.46	gold quality
cingulate cortex	UBERON:0003027	98.43	gold quality
anterior cingulate cortex	UBERON:0009835	98.43	gold quality
right frontal lobe	UBERON:0002810	98.14	gold quality
right lung	UBERON:0002167	98.09	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.95	gold quality
adult organism	UBERON:0007023	97.71	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.68	gold quality
hypothalamus	UBERON:0001898	97.56	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.46	gold quality
frontal cortex	UBERON:0001870	97.39	gold quality
ileal mucosa	UBERON:0000331	97.33	gold quality
lower lobe of lung	UBERON:0008949	97.31	gold quality
upper lobe of lung	UBERON:0008948	97.22	gold quality
upper lobe of left lung	UBERON:0008952	97.20	gold quality
ventral tegmental area	UBERON:0002691	97.16	gold quality
pons	UBERON:0000988	97.15	gold quality
prefrontal cortex	UBERON:0000451	97.11	gold quality
amygdala	UBERON:0001876	97.09	gold quality
orbitofrontal cortex	UBERON:0004167	97.07	gold quality
neocortex	UBERON:0001950	97.05	gold quality
superior vestibular nucleus	UBERON:0007227	97.00	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	20.51
E-GEOD-125970	yes	15.34
E-MTAB-7606	no	295.44
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, FOS, NRF1, PHOX2B

miRNA regulators (miRDB)

29 targeting HPCAL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-6861-3P	99.60	68.46	444
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-412-3P	98.86	66.89	712
HSA-MIR-6754-3P	98.84	66.60	889
HSA-MIR-6811-3P	98.62	66.54	944
HSA-MIR-6880-5P	98.08	65.59	1282
HSA-MIR-6847-5P	97.93	66.74	1808
HSA-MIR-4257	97.86	68.05	1190
HSA-MIR-7154-3P	97.65	65.02	985
HSA-MIR-3116	97.07	65.78	1324
HSA-MIR-874-3P	95.02	65.66	806

Literature-anchored findings (GeneRIF, showing 11)

• VILIP-3 immunostaining was found to be reduced in Alzheimer brains; immunoreactive material was detected in close association with amyloid plaques and neurofibrillar tangles, typical pathologic hallmarks of AD (PMID:11173883)
• visinin-like protein-3 interacts with microsomal cytochrome b5 in a Ca2+-dependent manner (PMID:14739275)
• The interaction of human VILIP1 and VILIP3 with divalent cations was explored using circular dichroism and fluorescence measurement. (PMID:16703469)
• HPCAL1 did not appreciably influence the ability of WT PHOX2B. (PMID:23873030)
• Results show that in the presence of calcium, N-myristoylation significantly increases the kinetic rate of VILIP adsorption to the membrane. (PMID:25019684)
• Secreted HPCAL1 protein in the plasma dropped dramatically in hepatocellular carcinoma patients relative to controls. (PMID:26659654)
• The myristoylated VILIP-3 protein structure determined in this study is quite different. (PMID:27820860)
• These studies elucidate the tumour-promoting activity of HPCAL1. They also offer an innovative therapeutic strategy focusing on the HPCAL1-Wnt/b-catenin axis to regulate proliferation and development of Glioblastoma. (PMID:30843345)
• Hippocalcin-like 1 is a key regulator of LDHA activation that promotes the growth of non-small cell lung carcinoma. (PMID:35102488)
• Expressional and prognostic value of HPCAL1 in cholangiocarcinoma via integrated bioinformatics analyses and experiments. (PMID:35645147)
• Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling. (PMID:36438486)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	hpcal1	ENSDARG00000022763
mus_musculus	Hpcal1	ENSMUSG00000071379
rattus_norvegicus	Hpcal1	ENSRNOG00000005492
drosophila_melanogaster	CG7646	FBGN0036926
drosophila_melanogaster	CG5890	FBGN0039380
caenorhabditis_elegans	ncs-2	WBGENE00003564
caenorhabditis_elegans		WBGENE00015867

Paralogs (14): CLXN (ENSG00000034239), GUCA1A (ENSG00000048545), NCALD (ENSG00000104490), NCS1 (ENSG00000107130), RCVRN (ENSG00000109047), GUCA1B (ENSG00000112599), KCNIP3 (ENSG00000115041), HPCAL4 (ENSG00000116983), KCNIP2 (ENSG00000120049), HPCA (ENSG00000121905), GUCA1C (ENSG00000138472), VSNL1 (ENSG00000163032), KCNIP1 (ENSG00000182132), KCNIP4 (ENSG00000185774)

Protein

Protein identifiers

Hippocalcin-like protein 1 — P37235 (reviewed: P37235)

Alternative names: Calcium-binding protein BDR-1, HLP2, Visinin-like protein 3

All UniProt accessions (5): P37235, C9JW46, E9PC71, H7BZC1, Q6FGY1

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the calcium-dependent regulation of rhodopsin phosphorylation.

Subcellular location. Membrane.

Miscellaneous. Probably binds two or three calcium ions.

Similarity. Belongs to the recoverin family.

RefSeq proteins (5): NP_001245286, NP_001245287, NP_001245288, NP_002140, NP_602293 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR028846	Recoverin	Family

Pfam: PF13499

UniProt features (38 total): binding site 15, helix 10, domain 4, sequence conflict 3, strand 3, initiator methionine 1, chain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5T7C	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P37235-F1	87.25	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (15): 84; 109; 111; 113; 115; 120; 157; 159; 161; 163; 168; 73 …

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 276 (showing top): AHRARNT_01, chr2p25, MODULE_264, RACCACAR_AML_Q6, RIZKI_TUMOR_INVASIVENESS_3D_DN, XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP, AMIT_EGF_RESPONSE_480_MCF10A, MODULE_120, CEBP_Q2, AML_Q6, IRF1_Q6, LASTOWSKA_COAMPLIFIED_WITH_MYCN, IRF_Q6, AACTTT_UNKNOWN, NGUYEN_NOTCH1_TARGETS_DN

GO Biological Process (1): regulation of signal transduction (GO:0009966)

GO Molecular Function (3): calcium ion binding (GO:0005509), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
metal ion binding	1
binding	1
cation binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2223 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HPCAL1	RHOA	P06749	610
HPCAL1	CYB5B	O43169	526
HPCAL1	CYB5A	P00167	521
HPCAL1	PHOX2B	Q99453	502
HPCAL1	SLC66A3	Q8N755	470
HPCAL1	GUF1	Q8N442	434
HPCAL1	NOL10	Q9BSC4	431
HPCAL1	CPSF3	Q9UKF6	430
HPCAL1	PDE6D	O43924	425
HPCAL1	NAIP	Q13075	406
HPCAL1	LRIT2	A6NDA9	405
HPCAL1	NUBP2	Q9Y5Y2	398
HPCAL1	EFCAB3	Q8N7B9	394
HPCAL1	SCN9A	Q15858	393
HPCAL1	SUSD2	Q9UGT4	391

IntAct

218 interactions, top by confidence:

A	B	Type	Score
ESR1	ESR1	psi-mi:“MI:0914”(association)	0.870
KRTAP10-8	HPCAL1	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-9	HPCAL1	psi-mi:“MI:0915”(physical association)	0.720
HPCAL1	C1QTNF2	psi-mi:“MI:0915”(physical association)	0.720
HPCAL1	KRTAP10-9	psi-mi:“MI:0915”(physical association)	0.720
C1QTNF2	HPCAL1	psi-mi:“MI:0915”(physical association)	0.720
HPCAL1	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
HMG20A	HPCAL1	psi-mi:“MI:0915”(physical association)	0.670
HPCAL1	HMG20A	psi-mi:“MI:0915”(physical association)	0.670
HPCAL1	DTX2	psi-mi:“MI:0915”(physical association)	0.670
HPCAL1	ATXN1	psi-mi:“MI:0915”(physical association)	0.670
MGLL	HPCAL1	psi-mi:“MI:0915”(physical association)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
HPCAL1	C19orf44	psi-mi:“MI:0915”(physical association)	0.600

BioGRID (124): KRTAP5-9 (Two-hybrid), HMG20A (Two-hybrid), KRTAP4-2 (Two-hybrid), C1QTNF2 (Two-hybrid), KRTAP10-7 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-1 (Two-hybrid), KRTAP10-5 (Two-hybrid), KRTAP10-8 (Two-hybrid), KRTAP10-3 (Two-hybrid), NOTCH2NL (Two-hybrid), HPCAL1 (Affinity Capture-MS), HPCAL1 (Affinity Capture-MS), HPCAL1 (Affinity Capture-MS), HPCAL1 (Affinity Capture-MS)

ESM2 similar proteins: A9JTH1, B3DLU1, B3VSB7, B5FZ84, P29104, P29105, P35332, P36608, P37235, P37236, P42324, P42325, P61601, P61602, P62166, P62167, P62168, P62748, P62749, P62758, P62759, P62760, P62761, P62762, P62763, P62764, P84074, P84075, P84076, Q06AT0, Q06AT1, Q09711, Q16982, Q28IM6, Q4PL64, Q4R4N4, Q4R5F7, Q5PQN0, Q5R632, Q5R6S5

Diamond homologs: A9JTH1, B3DLU1, B3VSB7, B5FZ84, O73761, O73762, O73763, O95843, P21457, P22728, P25296, P29104, P29105, P31227, P34057, P35243, P35332, P36608, P36609, P37235, P37236, P42322, P42324, P42325, P43080, P43081, P46065, P51177, P61601, P61602, P62166, P62167, P62168, P62748, P62749, P62758, P62759, P62760, P62761, P62762

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 111 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	5	50.8×	5e-06
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	5	44.8×	6e-06
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	5	44.8×	6e-06
Activation of BH3-only proteins	5	33.1×	3e-05
RHO GTPases activate PKNs	5	21.1×	2e-04
Intrinsic Pathway for Apoptosis	5	19.5×	2e-04
Translocation of SLC2A4 (GLUT4) to the plasma membrane	7	14.4×	4e-05
Apoptosis	6	13.4×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2569 predictions. Top by Δscore:

Variant	Effect	Δscore
2:10420134:AG:A	donor_loss	1.0000
2:10420135:GG:G	donor_loss	1.0000
2:10420136:G:T	donor_loss	1.0000
2:10420137:T:G	donor_loss	1.0000
2:10422982:GGCC:G	acceptor_gain	1.0000
2:10318210:A:AG	acceptor_gain	0.9900
2:10318211:G:GG	acceptor_gain	0.9900
2:10420133:C:T	donor_gain	0.9900
2:10422201:G:GA	donor_gain	0.9900
2:10422978:C:A	acceptor_gain	0.9900
2:10422978:CGCA:C	acceptor_loss	0.9900
2:10422979:GCA:G	acceptor_loss	0.9900
2:10422980:CA:C	acceptor_loss	0.9900
2:10422981:A:AC	acceptor_loss	0.9900
2:10422981:A:AG	acceptor_gain	0.9900
2:10422981:AG:A	acceptor_gain	0.9900
2:10422982:G:GT	acceptor_gain	0.9900
2:10422982:GG:G	acceptor_gain	0.9900
2:10422982:GGC:G	acceptor_gain	0.9900
2:10423066:G:GT	donor_gain	0.9900
2:10423067:C:T	donor_gain	0.9900
2:10426718:CTGCA:C	acceptor_loss	0.9900
2:10426719:TGCA:T	acceptor_loss	0.9900
2:10426720:GCA:G	acceptor_loss	0.9900
2:10426721:CA:C	acceptor_loss	0.9900
2:10426722:A:AG	acceptor_gain	0.9900
2:10426722:A:T	acceptor_loss	0.9900
2:10426723:G:GG	acceptor_gain	0.9900
2:10303175:CAGGT:C	donor_loss	0.9800
2:10303176:AGGTA:A	donor_loss	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000024924 (2:10419554 TAG>T), RS1000047474 (2:10410921 C>G), RS1000048108 (2:10338826 G>T), RS1000075751 (2:10300967 C>T), RS1000086534 (2:10353608 C>T), RS1000093593 (2:10301263 C>G,T), RS1000111710 (2:10375180 C>T), RS1000121203 (2:10360575 C>A,T), RS1000137144 (2:10424193 G>A), RS1000206622 (2:10345324 C>T), RS1000220466 (2:10314417 G>A,C), RS1000229847 (2:10380891 G>A,T), RS1000300396 (2:10306949 C>T), RS1000323086 (2:10397638 G>A), RS1000329833 (2:10421860 C>G,T)

Disease associations

OMIM: gene MIM:600207 | disease phenotypes: MIM:116700

GenCC curated gene-disease

Mondo (1): cataract 13 with adult I phenotype (MONDO:0007289)

Orphanet (1): Early onset non-syndromic cataract (Orphanet:91492)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002720_5	Kidney function decline traits	3.000000e-06
GCST005173_64	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	8.000000e-06
GCST006482_8	Lung function (FEV1/FVC)	9.000000e-11
GCST012485_1	Cerebral amyloid angiopathy x sex interaction in Alzheimer’s disease	1.000000e-07
GCST012490_12	Femur bone mineral density x serum urate levels interaction	1.000000e-13
GCST012490_464	Femur bone mineral density x serum urate levels interaction	6.000000e-10
GCST90002401_415	Platelet distribution width	6.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004723	coronary artery calcification
EFO:0004713	FEV/FVC ratio
EFO:0008343	sex interaction measurement
EFO:0004531	urate measurement
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295755 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	6
Tobacco Smoke Pollution	affects expression, increases expression, increases methylation	4
sodium arsenite	decreases expression, increases abundance, increases expression	3
Cadmium Chloride	increases abundance, increases expression	3
Particulate Matter	decreases expression, increases abundance, increases expression	3
bisphenol A	affects expression, affects cotreatment, increases methylation	2
Arsenic Trioxide	increases expression, affects cotreatment	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Benzo(a)pyrene	affects methylation	2
Cisplatin	decreases expression, affects response to substance	2
Estradiol	affects cotreatment, decreases expression, affects expression	2
Tretinoin	affects cotreatment, increases expression	2
Cyclosporine	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	affects methylation	1
nickel sulfate	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
desloratadine	decreases reaction, increases degradation, decreases expression, decreases myristoylation, affects response to substance	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
jinfukang	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118973	Binding	Binding affinity to HPCAL1 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1TT	Abcam HeLa HPCAL1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.